Avaliação da eficácia da suplementação mineral e da vacinação contra doenças reprodutivas em combinação no aumento da taxa de concepção em fêmeas bovinas

• Autor(a) principal: Pereira, Raphaella Arantes
• Data de Publicação: 2018
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFU
• Texto Completo: https://repositorio.ufu.br/handle/123456789/22968
• topic: Fertilidade; Fertility; Reprodução; Reproduction; Eficiência Reprodutiva; Reproductive Efficiency; Fosfosal; Fosfosal; Bovigen; Bovigen; CNPQ::CIENCIAS AGRARIAS::ZOOTECNIA

Agribusiness is today the main pillar that sustains Brazil's economy. While the other sectors feel the ef- fects of the crisis, agribusiness, despite the recession, continues to grow. Among the emerging seg- ments, livestock production increased by 6.36% in 2014 (CNA, 2014). With regard to herd health, breeding disorders in cattle are multifactorial and multiethnic, and may be infectious or non-in- fectious. In this context, the objective of this study was to evaluate the effectiveness of the combination of Fosfosal® and Bovigen® Repro Total SE in the reduction of infectious reproductive disorders and in design rate of bovine females. A total of 728 Nelore cows were used in this study and divided into two groups: 1- Control (n = 365) and 2-Fosfosal®/Vaccine (n = 363). For this, females (group Fosfosal®/Vaccine) received two doses of intramuscular Bovigen with interval of 21 days. Subsequently, all females were undergo an ovulation synchronization protocol and IATF. The protocol were initiated on a random day of estrus cycle (D0) in which females were received an intravaginal progesterone device, 2 mg of intramuscular estradiol ben- zoate and 15 mL of Fosfosal (group Fosfosal®/Vaccine). Eight days after (D8), the device were removed and 1 mg of estradiol cypionate, 500 μg cloprostenol sodium and 300 IU intramuscular eCG were gave. The IATF were performed 48 hours after the removal of the device, which were evaluate the expression of estrus (via estrotect) and size of ovulatory follicle. In the D40 and D100 were carried out ultrasonographic evaluations for gestational diagnosis and calculation of gestational loss. About to the increase in conception rate, the Fosfosal®/Vaccine tested group presented superior results to the Control group at 30 and 90 days after AI, as well as satisfactory abortion rate results.